Safety Profile of Genvoya® Analyzed Through FAERS Database
Author Information
Author(s): Wang Chengliang, Zhang Yan, Tang Xiting, Zhang Guoping, Chen Li
Primary Institution: People’s Hospital of Ganzi Tibetan Autonomous Prefecture, Kangding, Sichuan, China
Hypothesis
This study aims to evaluate and understand the safety profile of Genvoya® by analyzing adverse drug event reports from the FAERS database.
Conclusion
Multiple adverse reactions were observed with the use of Genvoya®, highlighting the need for clinicians to monitor these reactions closely.
Supporting Evidence
- Common adverse events included weight gain, drug interactions, and increased viral load.
- New potential adverse reactions such as fat redistribution and HIV-associated neurocognitive disorders were identified.
- Reports from male patients accounted for 74.33% of the total adverse event reports.
Takeaway
This study looked at reports of problems people had while taking Genvoya®, a medicine for HIV, and found that it can cause several side effects that doctors need to watch out for.
Methodology
Data were obtained from the FAERS database, focusing on reports where Genvoya® was the primary suspected drug, and analyzed using disproportionality analysis methods.
Potential Biases
The geographic distribution of reports may lead to a systematic bias, as most data come from developed countries.
Limitations
The study has limitations including reporting biases and incomplete information, and it is restricted to a single drug analysis.
Participant Demographics
The majority of reports were from male patients (74.33%) aged 18-65 years.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website